

CORRECTION

Open Access



# Correction: Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria

Filippo Manti<sup>1</sup>, Stefania Caviglia<sup>2</sup>, Chiara Cazzorla<sup>3</sup>, Annamaria Dicintio<sup>4</sup>, Andrea Pilotto<sup>5</sup> and Alessandro P. Burlina<sup>6\*</sup> 

**Correction: Orphanet Journal of Rare Diseases (2022) 17:443**

<https://doi.org/10.1186/s13023-022-02488-2>

Following publication of the original article [1], we have been notified that Table 2, column “Pediatric Patient” should be corrected as per below:

DGS (Forward and Reverse)

Also, reference 40 should be as follows:

40. Quinn J, Georgiadis A, Lewis HB, Jurecki E. Measuring burden of illness in phenylketonuria (PKU): development of the PKU symptom severity and impacts scale as a robust patient-reported outcome. *Adv Ther.* 2022;39:971–91.

Published online: 03 March 2023

The original article can be found online at <https://doi.org/10.1186/s13023-022-02488-2>.

\*Correspondence:

Alessandro P. Burlina  
alessandro.burlina@aulss7.veneto.it

<sup>1</sup> Unit of Child Neurology and Psychiatry, Department of Human Neuroscience, University of Rome La Sapienza, Rome, Italy

<sup>2</sup> Unit of Clinical Psychology, Department of Neurosciences, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

<sup>3</sup> Division of Inborn Metabolic Diseases, Department of Pediatrics, University Hospital, Padua, Italy

<sup>4</sup> Department of Metabolic Diseases and Clinical Genetics, Giovanni XXIII Children Hospital, Azienda Ospedaliero-Universitaria Consorziale Policlinico, 70126 Bari, Italy

<sup>5</sup> Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

<sup>6</sup> Neurology Unit, St. Bassiano Hospital, Bassano del Grappa, Italy

## Reference

1. Manti F, Caviglia S, Cazzorla C, Dicintio A, Pilotto A, Burlina AP. Expert opinion of an Italian working group on the assessment of cognitive, psychological, and neurological outcomes in pediatric, adolescent, and adult patients with phenylketonuria. *Orphanet J Rare Dis.* 2022;17(1):443. <https://doi.org/10.1186/s13023-022-02488-2>.

## Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.